Mala K. Talekar

The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).

Shannon L. Maude, George Hucks, Alix E. Seif et al. · Journal of Clinical Oncology · 2017 · 94 citations

Cell Therapy, Immunology, Cd4 T Cell Responses +16

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Shannon L. Maude, David M. Barrett, Susan R. Rheingold et al. · Blood · 2016 · 80 citations

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

Varun V. Prabhu, Mala K. Talekar, Amriti R. Lulla et al. · Cell Cycle · 2017 · 54 citations · Full text

Immunology, Pathology, Hematological Malignancies +19

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Ajay K. Nooka, Keith Stockerl‐Goldstein et al. · Blood · 2020 · 48 citations

Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10

Joshua E. Allen, Varun V. Prabhu, Mala K. Talekar et al. · Cancer Research · 2015 · 45 citations · Full text